Stem cell transplant trial for non-cancer blood disorders
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a non-cancer disorder that can be treated with a donor stem cell transplant
- Your non-cancer disorder is clearly diagnosed, or it is unclear but genetic testing did not find a specific cause (approved by the study doctor)
- You are under 50 years old
- You have a donor option: a close match (HLA-matched related or unrelated) with specific matching rules (or a small, allowed mismatch)
- Your donor stem cells meet study target counts (bone marrow or blood stem cells, if used)
- You do not have major heart, lung, or kidney problems and you are not actively sick with certain infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This Phase 2 study looks at a specific type of stem cell transplant that uses donor stem cells with immune cells removed, to treat certain high-risk leukemias and lymphomas. It aims to reduce relapse risk and improve outcomes in people who may need a transplant but have specific disease features.
Hear when a new Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.